Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL TRAUMATIC BRAIN INJURY THERAPEUTICS INDUSTRY
2.1 Summary about Traumatic Brain Injury Therapeutics Industry
2.2 Traumatic Brain Injury Therapeutics Market Trends
2.2.1 Traumatic Brain Injury Therapeutics Production & Consumption Trends
2.2.2 Traumatic Brain Injury Therapeutics Demand Structure Trends
2.3 Traumatic Brain Injury Therapeutics Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Acetylcholinesterase Inhibitors
4.2.2 Erythropoietin
4.2.3 Growth Hormone
4.2.4 Stem Cells
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Focal TBI
4.3.2 Open TBI
4.3.3 Closed TBI
4.3.4 Diffuse TBI
4.3.5 Primary TBI
4.3.6 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Acetylcholinesterase Inhibitors
5.2.2 Erythropoietin
5.2.3 Growth Hormone
5.2.4 Stem Cells
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Focal TBI
5.3.2 Open TBI
5.3.3 Closed TBI
5.3.4 Diffuse TBI
5.3.5 Primary TBI
5.3.6 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Acetylcholinesterase Inhibitors
6.2.2 Erythropoietin
6.2.3 Growth Hormone
6.2.4 Stem Cells
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Focal TBI
6.3.2 Open TBI
6.3.3 Closed TBI
6.3.4 Diffuse TBI
6.3.5 Primary TBI
6.3.6 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Acetylcholinesterase Inhibitors
7.2.2 Erythropoietin
7.2.3 Growth Hormone
7.2.4 Stem Cells
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Focal TBI
7.3.2 Open TBI
7.3.3 Closed TBI
7.3.4 Diffuse TBI
7.3.5 Primary TBI
7.3.6 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Acetylcholinesterase Inhibitors
8.2.2 Erythropoietin
8.2.3 Growth Hormone
8.2.4 Stem Cells
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Focal TBI
8.3.2 Open TBI
8.3.3 Closed TBI
8.3.4 Diffuse TBI
8.3.5 Primary TBI
8.3.6 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Acetylcholinesterase Inhibitors
9.2.2 Erythropoietin
9.2.3 Growth Hormone
9.2.4 Stem Cells
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Focal TBI
9.3.2 Open TBI
9.3.3 Closed TBI
9.3.4 Diffuse TBI
9.3.5 Primary TBI
9.3.6 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 SFC Fluidics LLC
10.1.2 Banayan Biomarkers Inc.
10.1.3 BHR Pharma LLC
10.1.4 Cerora Inc.
10.1.5 ElMindA Ltd.
10.1.6 Grace Laboratories LLC
10.1.7 KeyNeurotek Pharmaceuticals AG
10.1.8 Luoxis Diagnostics
10.1.9 Neuro Assessment Systems
10.1.10 Neurovive Pharmaceuticals AB
10.1.11 Oxygen Biotherapeutics Inc.
10.1.12 Phlogistix LLC
10.1.13 Neurohealing Pharmaceuticals
10.1.14 Neuren Pharmaceuticals Ltd.
10.1.15 Remedy Pharmaceuticals Inc.
10.1.16 Biodirection Inc.
10.1.17 Brainscope Company Inc.
10.1.18 TEVA Pharmaceutical Industries Ltd.
10.1.19 Vasopharm
10.2 Traumatic Brain Injury Therapeutics Sales Date of Major Players (2017-2020e)
10.2.1 SFC Fluidics LLC
10.2.2 Banayan Biomarkers Inc.
10.2.3 BHR Pharma LLC
10.2.4 Cerora Inc.
10.2.5 ElMindA Ltd.
10.2.6 Grace Laboratories LLC
10.2.7 KeyNeurotek Pharmaceuticals AG
10.2.8 Luoxis Diagnostics
10.2.9 Neuro Assessment Systems
10.2.10 Neurovive Pharmaceuticals AB
10.2.11 Oxygen Biotherapeutics Inc.
10.2.12 Phlogistix LLC
10.2.13 Neurohealing Pharmaceuticals
10.2.14 Neuren Pharmaceuticals Ltd.
10.2.15 Remedy Pharmaceuticals Inc.
10.2.16 Biodirection Inc.
10.2.17 Brainscope Company Inc.
10.2.18 TEVA Pharmaceutical Industries Ltd.
10.2.19 Vasopharm
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
